Keywords: MicuRx Pharma, Shanhai MengKe Pharma, Joint venture, MRX-I, Antibiotic, China
MicuRx joins forces with VC for next-generation antibiotic for China
Article | 24 October 2012
MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics, and China-based Shanghai ZhangJiang Biomedical Industry Venture Capital yesterday announced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
